Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Capital Royalty To Offer Debt With New $1 Billion Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

As the royalty field grows more crowded, the health care investor is turning away from passive royalties, the core strategy of its first fund, to become a lender to companies with products on the market or already approved.

You may also be interested in...



DRI Capital To Pursue Phase III Assets With Some Of Its Third Royalty Fund

Toronto-based health care royalty acquirer raises a $1.45 billion third fund, which it says should last between three-and-a-half and five years. It is mainly sticking with its prior investment strategy, although for the first time DRI will look at acquiring royalty rights to promising Phase III candidates.

Financings Of The Fortnight: Why Are Royalty-Based Financings On The Rise Again?

Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.

TearScience Secures $70 Million For One-Of-A-Kind Eye Device

TearScience Inc. is ready to go into full-scale commercialization for a new device treatment for the most prevalent form of dry eye. In late February, the young company secured up to $70 million from HealthCare Royalty Partners to help make that happen.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel